Lv4
540 积分 2026-01-06 加入
Interstitial lung disease biomarkers: a systematic review and meta-analysis
10天前
已完结
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
11天前
已完结
Drug-induced interstitial lung disease: a narrative review of a clinical conundrum
12天前
已完结
Trilaciclib: First Approval
1个月前
已完结
Discovery of Potent and Selective CDK4/6 Inhibitors for the Treatment of Chemotherapy-Induced Myelosuppression
1个月前
已完结
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
1个月前
已完结
Sacituzumab tirumotecan improves OS in mTNBC
2个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
2个月前
已完结
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
4个月前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial
4个月前
已完结
皖公网安备34019202002308
